Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats
Vincent Marty, Mehdi Farokhnia, Joseph J. Munier, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Mette Kruse Klausen, Morgane Thomsen, Gitta Wörtwein, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 625-641
Open Access | Times Cited: 108
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 81
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Cajsa Aranäs, Christian E. Edvardsson, Olesya T. Shevchouk, et al.
EBioMedicine (2023) Vol. 93, pp. 104642-104642
Open Access | Times Cited: 55
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Fatima Quddos, Zachary Hubshman, Allison N. Tegge, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 53
The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
Elisabet Jerlhag
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 36
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 34
Case Report: Semaglutide-associated depression: a report of two cases
Jiarui Li, Jinya Cao, Jing Wei, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 25
GPCRs involved in metabolic diseases: pharmacotherapeutic development updates
Hongchuan Jin, Hui Chen, Li Xie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 7, pp. 1321-1336
Closed Access | Times Cited: 11
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice
Paul Brennan, Oliver Tavabie, Wenhao Li, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 577-582
Open Access | Times Cited: 10
Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice
Weizhen Liu, Ziliang Wang, Wang Wang, et al.
Neurochemical Research (2024) Vol. 49, Iss. 4, pp. 1061-1075
Open Access | Times Cited: 9
Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)
Mette Kruse Klausen, Tugba Kuzey, Jens Pedersen, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e086454-e086454
Open Access | Times Cited: 1
Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin
Maximilian Tufvesson‐Alm, Olesya T. Shevchouk, Elisabet Jerlhag
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 20
New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease
Luis Antonio Díaz, Gerald Scott Winder, Lorenzo Leggio, et al.
Hepatology (2023)
Closed Access | Times Cited: 17
The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis
Fares Qeadan, Ashlie McCunn, Benjamin Tingey
Addiction (2024)
Open Access | Times Cited: 7
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 6
Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease
Sundararajan Mahalingam, Ramesh Bellamkonda, Madan Kumar Arumugam, et al.
Biochemical Pharmacology (2023) Vol. 213, pp. 115613-115613
Open Access | Times Cited: 13
Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study
Joana Nicolau, María Isabel Tamayo, Pilar Sanchís, et al.
Journal of Addictive Diseases (2024) Vol. 42, Iss. 4, pp. 535-543
Closed Access | Times Cited: 5
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder
Sophie Köhne, Thomas Hillemacher, Alexander Glahn, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 219-232
Closed Access | Times Cited: 5
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Silvia Tempia Valenta, Alba Nicastri, Federica Perazza, et al.
Current Treatment Options in Psychiatry (2024)
Closed Access | Times Cited: 5
A Complex Interplay between Nutrition and Alcohol use Disorder: Implications for Breaking the Vicious Cycle
Brooke White, Sunil Sirohi
Current Pharmaceutical Design (2024) Vol. 30, Iss. 23, pp. 1822-1837
Closed Access | Times Cited: 4
Oleoylethanolamide ameliorates allergic asthma and atopic dermatitis via activation of GPR119
Jung-Eun Lee, Dong‐Soon Im
International Immunopharmacology (2025) Vol. 149, pp. 114258-114258
Closed Access
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, et al.
JAMA Psychiatry (2025)
Closed Access
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder
Elisabet Jerlhag
Endocrinology (2025) Vol. 166, Iss. 4
Open Access
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study
Feras Al-Moussally, Saud Khan, Vinay Katukuri, et al.
Drugs (2025)
Closed Access
Page 1 - Next Page

Scroll to top